A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
for CRC (Colorectal Cancer)
Drug: Bevacizumab
80 locations incl. Chandler
Sponsor: Incyte Corporation
Sex: All·Age: 18+
Code: NCT07284849·Phase 3·Recruiting